Mr. Lankau is an experienced bio-pharmaceutical executive with over 40 years of management and consulting experience in developing and commercializing pharmaceutical products. He is a Principal in Lankau Consulting LLC, which has been providing advisory and consulting services to support boards of directors and senior management of pharmaceutical and biotechnology companies, as well as venture capital, private equity and law firms since 2014.
He has been an expert witness in more than 16 litigation/arbitration cases in the past 5 years and has testified at deposition and/or trial in 8 cases.
Mr. Lankau was the President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company. He previously served as the company’s President and Chief Operating Officer and as Senior Vice President, US Commercial Business. While CEO, he led the company to become an industry leader in specialty pharma, as well as developing its pipeline which included 12 product acquisitions and/or licensing transactions. He was also a member of its Board of Directors.
Mr. Lankau was Executive Chairman of the Board for Nautilus Neurosciences, Inc., a commercial stage, private equity-backed, neurology-focused specialty pharmaceutical company, which sold its business to Depomed, Inc. (now Assertio Therapeutics). He was responsible for the overall management of the company and directed the transaction process which resulted in the negotiation and sale of the company’s assets.
He is the former Chairman and CEO of Logical Therapeutics, Inc., a venture capital backed development stage biopharmaceutical company which developed compounds to improve the gastrointestinal tolerability of NSAID’s in the chronic treatment of inflammatory disease. He directed all aspects for the pre-clinical and clinical development including FDA submissions.
Earlier in his career, Mr. Lankau was Vice President, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi) in multiple commercial roles, and had most recently been Vice President, Sales-US Pharmaceuticals.
Mr. Lankau was most recently a Member of the Board of Directors of Quion Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing products that help address major societal issues including the opioid epidemic and the military veteran suicide rate and chronic rare skin diseases such as Netherton syndrome and Dystrophic Epidermolysis Bullosa (DEB).
Previously, Mr. Lankau was a Member of the Board of Directors for Cipla Limited, one of the top pharmaceutical companies in India. Cipla is a leading global healthcare company which uses innovation and technology for developing branded and generic pharmaceutical products and devices.
Mr. Lankau was also a Member of the Board of Directors of InvaGen Pharmaceuticals, Inc., a leading generic pharmaceutical company, engaged in development, manufacturing, marketing and distributing generic pharmaceuticals.
Mr. Lankau served as a Member of the Board of Directors , and was formerly Chairman of the Board, of Phosphagenics Limited (now Avecho Biotechnology Ltd.), an Australian research-based biotechnology company that discovers and develops novel approaches to enhance the delivery, effectiveness, and/or tolerability of proven pharmaceutical, consumer, and animal health products.
Mr. Lankau served as a Member of the Board of Directors for ANI Pharmaceuticals, Inc., an integrated specialty and generic pharmaceutical company developing, manufacturing and marketing branded and generic prescription products.
Mr. Lankau can be reached directly at plankau@lankauconsulting.com.
Lankau Consulting has a network of well regarded pharmaceutical experts that it deploys in project services work, where the engagement calls for more functional expertise with content specific knowledge and experience. These areas include: